BBK Worldwide Blog

According to the Centers for Disease Control and Prevention (CDC), among the top ten leading causes of death in the United States per year are diseases that include heart disease (696,962), cancer (602,350), stroke (160,264), Alzheimer’s disease (134,242) and diabetes (102,188).¹ It makes sense, then, that there would be substantial clinical efforts to provide preventative and curative treatments for these conditions. However, when planning your trial to test the efficacy of your treatment, how often do you reflect on the actual patient population?

New survey findings reveal the importance of offering patients choice when it comes to improving clinical trial diversity, access, and engagement.

Patients want options, or choice, when it comes to clinical trial participation. New data from a recent Study Voices survey reveals the impact choice can have on participation. The findings empower clinical trial sponsors to shift from traditional clinical trial enrollment models to hybrid enrollment models.

DOWNLOAD NOW

A Diversified Outreach Strategy
Is Key to Clinical Trial Inclusivity

New Infographic Available for Download

Many clinical trial sponsors are seeking ways to enable hybrid study designs with ease and confidence. Our new infographic follows the patient's journey from consideration to enrollment to engagement throughout the study life cycle, with information to help sponsors create a more diverse and inclusive participation environment.

We are very excited to kick off the new year with the announcement that we have been acquired by Publicis Health, the healthcare communications leader that transforms healthcare marketing and communications into healthcare engagement.

Together, we share a commitment to the clinical trial experience and to enhancing understanding and access for all, and we look forward to joining the Publicis Health network. Our mission remains unchanged, as does our commitment to supporting you in advancing your clinical R&D efforts.

The clinical trial landscape saw a lot of changes in 2021, from decentralized clinical trial adoption to a greater emphasis on diversity and inclusion. But what’s in store for 2022? We asked our industry experts to weigh in with their predictions.

Earlier this week, Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, announced its partnership with BBK to provide concierge services for patients participating in its clinical studies. The services are designed to improve patients' and their caregivers' access to high-quality care and innovative treatments for their cancer.

Earlier this week, BBK's Senior Director of Patient Engagement Services Mike Johnson spoke with Outsourcing-Pharma to discuss the RSG^® Arrive travel program and its recent milestone of 20,000 completed trips.

In this in-depth interview, Mike discusses what sets this program apart from others as he highlights the concierge specialists who are experienced in understanding all the ramifications of a request, as it relates not only to arranging a travel itinerary but also ensuring the itinerary supports patient health, safety, and compliance. In addition, Mike shares insight into the significance of the milestone for BBK as well as the industry at large. Click here to read the full article.

Getting Decentralized Right

What Matters to Patients

In Part 2 of our two-part interview with Phil Kelly, we delve further into the patient perspective on decentralized clinical trials. We ask Phil Kelly to share his thoughts on patient needs, tools, technologies, and the patient experience.

If you are conducting a decentralized clinical trial or planning for one, this is a must-see segment, with valuable insight to leverage for success.

Getting Decentralized Right

What Matters to Patients

We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?

To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this two-part series on the patient perspective.

New eBook Available for Download

As we continue to focus our attention on underserved populations, we've just released a content-rich eBook full of guidance that study sponsors can leverage to create a more diverse and inclusive clinical trial environment. It features a bonus section with excerpts from our recent Q&A with Michele Russell-Einhorn, chief compliance officer and institutional official at Advarra, that provide an IRB's perspective on improving diversity and inclusion in clinical trials.